Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Inclusion Criteria:

• Signed informed consent.

• Subjects must be 18 years or older at the time of signing the informed consent.

Exclusion Criteria:

• Subjects with known severe or life-threatening hypersensitivity reaction to anyother CSU/HS treatment according to National Cancer Institute-Common TerminologyCriteria for Adverse Events (NCI-CTCAE).

• Subjects who have any other skin disease that may interfere with assessment of CSUor HS.

• Subjects who have an active infection or history of infection(s) as follows:

1. Any infection requiring systemic treatment within 14 days prior to baseline.

2. A history of opportunistic, recurrent, or chronic infections that, in theopinion of the Investigator, might cause this study to be detrimental to thesubject.

• Subjects with known progressed liver disease (Child-Pugh B or C)